ClinicalTrials.gg
CompletedNCT00547651Updated Nov 6, 2019

AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy

A Phase 3 interventional study of Amrubicin and Topotecan in Small Cell Lung Cancer, sponsored by Celgene. Completed at 140 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-06.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
637
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb — 2 open to participants now, 2 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Bristol-Myers Squibb.

Enrollment
2nd of 17
637 · median 92
Started
2007
the only one that year
Phase 3
3 of 19
1 open now
Registered
5th of 19
by date

Among the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2007, is one of 3 in phase 3, and was the 5th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This study drug (Amrubicin) is believed to work by stopping the tumor cells in your body from growing. The purpose of this study is to evaluate the effect of amrubicin compared to topotecan in the treatment of small cell lung cancer.

Read the detailed description

Small cell lung cancer represents approximately 13% of the cancers of the lung and presents as extensive stage disease in 60% to 70% of patients. Sites of metastases include bone (35%), liver (25%), bone marrow (20%), brain (10%), extrathoracic lymph nodes (5%), and subcutaneous masses (5%). Small-cell lung cancer has prominent markers of neuroendocrine differentiation.

The staging classification for SCLC is the 2-stage Veterans Administration Lung Study Group system that categorizes patients as having limited or extensive disease. Limited stage SCLC is disease confined to 1 hemithorax with or without adjacent mediastinal and/or supraclavicular lymph node involvement, but without a pleural effusion. This extent of disease can be included in a tolerable radiation field. Extensive-disease SCLC is any disease beyond the definition of limited-stage disease.

There are few proven treatment options for SCLC patients who fail first-line chemotherapy. New treatment strategies must be evaluated. The need to discover active agents with better toxicity profiles continues to be of great importance. Amrubicin may be an effective treatment for this population.

03

Conditions studied

  • Small Cell Lung Cancer

Keywords

  • Small Cell Lung Cancer
  • Lung Cancer
  • Limited Disease Sensitive Small Cell Lung Cancer
  • Extensive Disease Sensitive Small Cell Lung Cancer
  • Limited Disease Refractory Small Cell Lung Cancer
  • Extensive Disease Refractory Small Cell Lung Cancer
  • Refractory Small Cell Lung Cancer
  • Sensitive Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of SCLC at study entry according to the International Association for the Study of Lung Cancer (IASLC) histopathologic classification. Mixed or combined subtypes according to the IASLC are not allowed;
  • SCLC that is either sensitive (defined as a response including stable disease to platinum-based chemotherapy, with subsequent progression >/= 90 days after completing first-line chemotherapy) or (defined as best response to first-line platinum-based chemotherapy or progression \< 90 days after completing first-line chemotherapy);
  • Extensive or limited disease; patients with limited disease who are candidates for local or regional salvage radiation therapy must have been offered such treatment prior to participation in this study;
  • Radiographically documented progression after first-line treatment with platinum-based chemotherapy;
  • No more than 1 prior chemotherapy regimen;
  • At least 18 years of age;
  • performance status of 0 - 1

Exclusion criteria

Exclusion Criteria:

  • Chest radiotherapy with curative intent to the primary disease complex \</= 28 days prior to first dose; CNS radiotherapy \</= 21 days prior to first dose; radiotherapy to all other areas \</= 7 days prior to first dose;
  • Prior anthracycline, topotecan, or irinotecan treatment.
  • Prior anthracycline or topotecan treatment.
  • Patients with know history of seropositive (HIV) or patients who are receiving medications that would increase the risk of serious neutropenic complications
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
637 participants (actual)

Study arms

  • Experimental
    Amrubicin

    Amrubicin

    Drug: Amrubicin

  • Active comparator
    Topotecan

    Topotecan

    Drug: Topotecan

Interventions

  • Amrubicin for injection is supplied as 50-mg vials. Patients will receive 40 mg/m2 amrubicin as a 5-minute infusion once daily for 3 consecutive days starting on Day 1 of a 21-day course

    Also known as: amrubidin hydrochloride, Calsed, CNF3140

  • Topotecan for injection is supplied as 4-mg vials. Patients will receive 1.5 mg/m2 as a 30-minute infusion once daily for 5 consecutive days starting on Day 1 of a 21-day course

    Also known as: Topotecan hydrochloride, Hycamtin

06

What researchers measure

Primary outcomes

  1. The primary objective is to demonstrate superiority in overall survival of amrubicin compared with topotecan hydrochloride in patients with small cell lung cancer (SCLC) after failure of first-line chemotherapy.

    Time frame: Until death from any cause

Secondary outcomes

  1. To further characterize the clinical benefit of amrubicin compared with topotecan in terms of objective response rate

    Time frame: Until death

  2. To further characterize the clinical benefit of amrubicin compared with topotecan in terms of progression-free survival.

    Time frame: Until death

  3. To further characterize the clinical benefit of amrubicin compared with topotecan in terms of duration of response

    Time frame: Until death

  4. To further characterize the clinical benefit of amrubicin compared with topotecan in terms of time to tumor progression

    Time frame: Until death

  5. To further characterize the clinical benefit of amrubicin compared with topotecan in terms of safety

    Time frame: Until death

  6. To further characterize the clinical benefit of amrubicin compared with topotecan in terms of quality of life

    Time frame: Until death

07

Study locations

140 sites
  • Northwest Alabama Cancer Center
    Muscle Shoals, Alabama 35661, United States
  • Arizona Oncology Associates
    Tucson, Arizona 85704, United States
  • Little Rock Hematology Oncology Associates
    Little Rock, Arkansas 72205, United States
  • Cancer Care Associates of Fresno Medical Group, Inc.
    Fresno, California 93720, United States
  • Cedars-Sinai Outpatient Cancer Center
    Los Angeles, California 90048, United States
  • University of Colorado Health Science Centre
    Aurora, Colorado 80045, United States
  • Rocky Mountain Cancer Center - Midtown (Main)
    Denver, Colorado 80218, United States
  • Advanced Medical Specialties
    Miami, Florida 33176, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Cancer Centers of Florida, P.A.
    Ocoee, Florida 34761, United States
  • Florida Oncology Associates
    Orange Park, Florida 32073, United States
  • Sacred Heart Medical Oncology
    Pensacola, Florida 32504, United States
  • Medical Oncology Associates of Augusta
    Augusta, Georgia 30809, United States
  • Joliet Oncology-Hematology Associates, Ltd.
    Joliet, Illinois 60435, United States
  • Cancer & Hematology Specialists of Chicago (Main)
    Niles, Illinois 60714, United States
  • Illinois Cancer Care
    Peoria, Illinois 61615, United States
  • Cancer Care at Blessing Hospital
    Quincy, Illinois 62301, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 46227, United States
  • Hope Center
    Terre Haute, Indiana 47802, United States
  • Kansas City Cancer Center (Main)
    Overland Park, Kansas 66210, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Jayne Gurtler MD, Laura Brizn MD, Angelo Russo MD, and Janet Burroff MD, APMC
    Metairie, Louisiana 70006, United States
  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Maine Center for Cancer Medicine and Blood Disorders
    Scarborough, Maine 04074, United States
  • Sinai Hospital of Baltimore, Inc.
    Baltimore, Maryland 21215, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Alliance Hematology Oncology, P.A. (Main)
    Westminster, Maryland 21157, United States
  • Kalamazoo Hematology and Oncology
    Kalamazoo, Michigan 49048, United States
  • Michigan Hematology & Oncology Institute
    Southgate, Michigan 48195, United States
  • University of Minnesota Medical Center, Cancer Center
    Minneapolis, Minnesota 55455, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • St. Joseph Oncology, Inc.
    Saint Joseph, Missouri 64507, United States
  • Comprehensive Care Centers of Nevada (Main)
    Las Vegas, Nevada 89169, United States
  • New York Oncology Hematology, P.C.
    Latham, New York 12110-0610, United States
  • SUNY Upstate Medical University - Regional Oncology Center
    Syracuse, New York 13210, United States
  • Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina 27599, United States
  • Regional Cancer Care
    Durham, North Carolina 27704, United States
  • Cancer Centers of North Carolina (Main)
    Raleigh, North Carolina 27607, United States
  • Piedmont Hematology Oncology Associates
    Winston-Salem, North Carolina 27103, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Greater Dayton Cancer Center (Main)
    Kettering, Ohio 45409, United States
  • Cancer Care Associates
    Oklahoma City, Oklahoma 73112, United States
  • Cancer Care Associates
    Tulsa, Oklahoma 74136, United States
  • Willamette Valley Cancer Center (Main)
    Eugene, Oregon 97401-8122, United States
  • Medical Oncology Associates
    Kingston, Pennsylvania 18704, United States
  • Thomas Jefferson Memorial Hospital
    Philadelphia, Pennsylvania 19107, United States
  • UPMC Cancer Pavilion
    Pittsburgh, Pennsylvania 15232, United States
  • Cancer Centers of the Carolinas (Main)
    Greenville, South Carolina 29615, United States
  • The Sarah Cannon Research Institute/TN Oncology
    Nashville, Tennessee 37203, United States
  • Texas Oncology, P.A.
    Amarillo, Texas 79106, United States
  • Coastal Bend Cancer Center
    Corpus Christi, Texas 78463, United States
  • Texas Cancer Center at Medical City (Main)
    Dallas, Texas 75230-2510, United States
  • Texas Oncology, P.A. (Main)
    Dallas, Texas 75246, United States
  • West Texas Cancer Center-Texas Oncology
    Odessa, Texas 79761, United States
  • Texas Oncology, P.A.
    Webster, Texas 77598-4420, United States
  • Texoma Cancer Center
    Wichita Falls, Texas 76310, United States
  • Fairfax Northern Virginia Hematology/Oncology
    Fairfax, Virginia 22031, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Blue Ridge Cancer Care
    Roanoke, Virginia 24019, United States
  • Northwest Cancer Specialists - Vancouver (Main)
    Vancouver, Washington 98684, United States
  • Marshfield Clinic
    Marshfield, Wisconsin 54449, United States
  • Royal North Shore Hospital
    St. Leonards, New South Wales 2065, Australia
  • New South Wales Southern Medical Day Care Centre
    Wollongong, New South Wales 2500, Australia
  • The Princess Alexandra Hospital, Dept of Respiratory Medicine
    Woolloongabba, Queensland, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • The Queen Elizabeth Hospital
    Woodville South, SA 5011, Australia
  • Allgemeines Krankenhaus der Stadt Linz, Abteilung fur Atem und Lungenkrankheiten
    Linz, 4020, Austria
  • Klinikum Weis-Grieskirchen GmbH
    Wels, 4600, Austria
  • Allegemeines Krankenhaus Wien, Univ. Klinik fur Innere, Medizin I
    Wien, 1090, Austria
  • Krankenhaus Hietzing, 5 Med. Abteilung mit Onkologie
    Wien, 1130, Austria
  • UZ Brussel, Medical Oncology and Hematology
    Brussel, 1090, Belgium
  • Centre Hospitalier Notre-Dame et Reine Fabiola
    Charleroi, 6000, Belgium
  • Universitair Ziekenhuis Antwerpen, Dept. Respiratory Diseases
    Edegem, 2650, Belgium
  • UZ Gasthuisberg, UZ Leuven
    Leuven, 3000, Belgium
  • C.H.U. Sart-Tilman
    Liege, 4000, Belgium
  • III-rd Internal Department, District Dispensary for Oncology diseases with stationary(DDOncDIU)
    Plovdiv, 4004, Bulgaria
  • DDOncDIU Sofia District
    Sofia, 1233, Bulgaria
  • MHAT "Tsaritsa Yoanna"
    Sofia, 1504, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Sveta Marina"
    Varna, 9010, Bulgaria
  • Fraser Valley Cancer Centre-Surrey Memorial Hospital
    Surrey, British Columbia, Canada
  • London Regional Cancer Centre
    London, Ontario, Canada
  • Princess Margaret Hospital
    Toronto, Ontario, Canada
  • Humber River Regional Hospital
    Weston, Ontario, Canada
  • Royal Victoria Hospital
    Montreal, Quebec H3A 1A1, Canada
  • Fakultni Nemocnice Ostrava
    Ostrava-Poruba, Czechia
  • Faculty Hospital Motol
    Praha 5, 15006, Czechia
  • Fakultní Thomayerova nemocnice s poliklinikou
    Praha, 140 59, Czechia
  • Masarykova nemocnice v Ústí nad Labem
    Ústí nad Labem, 401 13, Czechia
  • Rikshospitalet, Finsen Center
    Copenhagen, 2100, Denmark
  • Herlev Hospital, Onkologisk afdeling R
    Herlev, 2730, Denmark
  • Odense Universitetshospital,Onkologisk afdeling R
    Odense C, 5000, Denmark
  • Centre François Baclesse
    Caen Cedex 5, 14076, France
  • Hôpital de la Croix-Rousse
    Lyon Cedex 04, 69317, France
  • CHU Montpellier - Unité de Cancérologie Thoracique
    Montpellier Cedex, 34295, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Zentralklinik Bad Berka GmbH
    Bad Berka, Germany
  • Charité Universitätsmedizin Berlin
    Berlin, 12200, Germany
  • Universitätsklinikum Essen Innere Klinik und Poliklinik
    Essen, 45122, Germany
  • Asklepios Fachkliniken Muenchen Gauting
    Gauting, 82131, Germany
  • Krankenhaus Grosshansdorf, Zentrum fur Pneumologie und Thoraxchirurgie
    Grosshansdorf, 22927, Germany

Showing the first 100 of 140 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, Steins M, Bosquee L, Bubis J, Nackaerts K, Trigo JM, Clingan P, Schutte W, Lorigan P, Reck M, Domine M, Shepherd FA, Li S, Renschler MF. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014 Dec 10;32(35):4012-9. doi: 10.1200/JCO.2013.54.5392. Epub 2014 Nov 10. PubMed 25385727 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2007 to primary completion in May 2011, 44 months.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 44 months is above that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2007
First posted
Oct 22, 2007
StartActual
Sep 1, 2007
Primary completionActual
May 1, 2011
CompletionActual
May 1, 2011
Results delay requested
Jul 19, 2011
Last update
Nov 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00547651
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Oct 22, 2007
Start date
Sep 1, 2007
Primary completion
May 1, 2011
Completion
May 1, 2011
Last update
Nov 6, 2019

Study contacts

Markus Renschler, M.D.
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amrubicin

Start the discussion